Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00719212 · ClinicalTrials.gov registry record · Phase 2

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

A Phase 2 study of Ovarian Neoplasms, sponsored by Translational Research in Oncology.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
20
Study locations

NCT00719212 is a Phase 2 study of Ovarian Neoplasms that has completed, run by Translational Research in Oncology. The registered enrollment target is 61 participants, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00719212, a Phase 2 study of Ovarian Neoplasms, has completed, sponsored by Translational Research in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.

Conditions Studied

Ovarian Neoplasms

Interventions

  • BIOLOGICAL AMG 479

Study Locations (20)

California

  • Comprehensive Blood and Cancer Center - Bakersfield
  • St Jude Heritage Healthcare - Fullerton
  • Wilshire Oncology Medical Group Inc - La Verne
  • LAC/USC Medical Center - Los Angeles
  • University of Southern California/ Norris Comprehensive Cancer Center - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • UCLA - Los Angeles
  • North Valley Hematology/ Oncology Medical Group - Northridge
  • Ventura County Hematology Oncology Specialists - Oxnard
  • Central Hematology Oncology Medical Group Inc. - Pasadena

Other

  • Tom Baker Centre - Calgary
  • Juravinski Cancer Center - Hamilton
  • CHUM Hôpital Notre Dama - Montreal
  • Jewish General Hospital - Montreal

Colorado

  • University of Colorado - Aurora

Illinois

  • University of Chicago - Chicago

Kansas

  • Cancer Center of Kansas - Wichita

Michigan

  • St Joseph Mercy Health System - Ann Arbor

Minnesota

  • Mayo Clinic - Rochester

Nevada

  • Comprehensive Cancer Centre of Nevada - Henderson

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2009-01
Est. Completion 2013-05
Phase Phase 2

Sponsor

Translational Research in Oncology

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00719212

The ClinicalTrials.gov registry entry for NCT00719212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (83% lower). The listed sponsor is Translational Research in Oncology, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which AMG 479 is the first listed.

NCT00719212 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Other, Colorado.

Frequently Asked Questions

What is clinical trial NCT00719212 about?

NCT00719212 is a clinical study titled "Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer". The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.

What is the current status of trial NCT00719212?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2009-01. Estimated completion is 2013-05.

What conditions does trial NCT00719212 study?

This clinical trial studies the following conditions: Ovarian Neoplasms.

What interventions are being tested in trial NCT00719212?

The interventions under investigation include: AMG 479 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00719212?

This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00719212 being conducted?

This trial has 20 study locations across California, Colorado, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.